Navigation Links
Zimmer to Expand Manufacturing Network
Date:2/5/2008

New Facility in Shannon, Ireland to Start Up in Late 2008

WARSAW, Ind., Feb. 5 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE and SWX: ZMH), a leader in the orthopaedics industry, announced today that it will expand its global manufacturing network by adding a 100,000 square foot plant in Shannon, Ireland.

"We are delighted to be adding a new Ireland facility to our global network," said David Dvorak, Zimmer Holdings President and CEO. "We are constantly assessing our worldwide operations and logistics network to maximize efficiency and customer service, and this project is a result of that process. We are grateful for the cooperation and encouragement of the national and local officials in Shannon and look forward to establishing a facility that utilizes the tremendous skills and expertise of the workforce to produce high technology medical devices."

Zimmer said it considered a number of sites before selecting Shannon, including its existing sites and other global locations. The Company expects to invest between $70 and 75 million (USD) over the next two years in its new facility in Shannon and plans to begin manufacturing operations in late 2008. Initial employment will be approximately 25 to 50 employees, with total employment expected to be approximately 250 in five years. At start-up, the facility will produce knee replacement implants, although other products could be added in the future. Shannon Development and Irish Development Agency officials provided incentives including tax rate adjustments and training grants; the Company did not disclose actual amounts.

Making the announcement in Ireland today, Minister for Enterprise, Trade and Employment, Micheal Martin T.D., said: "Zimmer's decision to establish at Shannon Free Zone adds significantly to Ireland's profile as a leading location for medical device companies in Europe. This investment is very welcome news for Shannon and was secured by Shannon Development
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Zimmer Holdings to Present at Merrill Lynch Health Care Conference
2. Zimmer Reports Fourth Quarter and 2007 Financial Results
3. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
4. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
5. Zimmer Holdings to Present at JPMorgan Healthcare Conference
6. Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee
7. Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman
8. Zimmer Holdings to Present at Upcoming Investor Conferences
9. Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
11. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...lifornia Health System Builds Resilient, Cost and ..., HOPKINTON, Mass., Dec. 2 EMC ...formation infrastructure solutions, today announce...S), a regional system of six hospitals spanning th...ervers and implemented business continuity functio...
(Date:12/2/2008)...NVER, Dec. 2 Barotz Dental is now ...ng LANAP(TM) (Laser Assisted New Attachment,Proce...col that is patented,and FDA approved for new att... LANAP removes diseased tissue, without removin...sue around teeth, minimizes pain and discomfort to...
(Date:12/2/2008)...SHERS, Ind., Dec. 2 A number of re...e in childhood obesity, the health risks in,overw...alue of cereals and,other foods kids consume. Ye...offers all natural, freeze-dried real fruit produc... but also provide most, if not all, of the daily f...
(Date:12/2/2008)... Zicam Cold & Flu Compa...ers stay one step ahead of cold and flu. , ...er 2, 2008 -- Matrixx Initiatives, Inc., makers of...h of the Zicam® Cold & Flu Companion mobil...d,s first Android-powered phone. The same mobile a...
Breaking Medicine News(10 mins):Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 2Health News:Moms Find Fun, Healthy Snacks That Help Fight Childhood Obesity 3Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 2Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 3
...ing weight by dietary changes and increased physic...condition where blood glucose// levels are higher ...ese are the results of a new study that was publis...Care, of women who participated in the Diabetes Pr...
...e being hit the most by obesity-related disorders....ne by doctors that fails to// detect these problem...ight divided by height- is used in the standard me...ing to the experts, East and South Asians were aff...
...n Canada ahead of HIV/AIDS, diabetes and car accid...inal communities. With World// Suicide Prevention ... from the Canadian Institutes of Health Research (...lenges posed by suicide, its causes and possible p...
...er a period of 30 years and has infected many peop...Recently, 3 people in Delhi// have tested positive...rs who transmit chikungunya fever to human. The N...able Diseases (NICD) tested 6 blood samples of whi...
Other Medicine News:Health News:Bladder Control following Weight loss in women with Prediabetes 2Health News:Bladder Control following Weight loss in women with Prediabetes 3Health News:Getting Serious About Suicide Prevention 2
(Date:12/2/2008)... -- Horizon Therapeutics, Inc., a,privately held ...o pivotal,Phase 3 trials evaluating its lead inve...rimary endpoints. HZT-501, a novel, proprietary fi... and famotidine, demonstrated a,statistically sig...al,anti-inflammatory drug (NSAID)-induced upper g...
(Date:12/1/2008)... A study has found that...que for imaging the breast, is not affected by eit...wo factors that limit the effectiveness of standar... will be presented today at the annual meeting of ... , , "The ability of PEM to detect cancer d...
(Date:12/1/2008)... S*BIO Pte Ltd today announced the initiation of a...orally-active JAK2 inhibitor, in leading medical c...pathic myelofibrosis (CIMF). , , The trial...ty of SB1518 in patients with CIMF and is expected...the study will assess the safety profile and evalu...
(Date:12/1/2008)...ne is a two-way switch that, if turned off, causes... that they lose their identity and become more lik...., Dec. 1 Scientists a...vered that a certain differentiated cell type is s...e constant expression of a gene called Prox1 to ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Major Stroke Risk Substantial After Minor Event 3A Study 6104 1Major Stroke Risk Substantial After Minor Event 3A Study 6104 2Major Stroke Risk Substantial After Minor Event 3A Study 6104 3Biomarkers predict risk for invasive breast cancer years before the tumor develops 6099 1Biomarkers predict risk for invasive breast cancer years before the tumor develops 6099 2Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Le 6094 1Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Le 6094 2Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Le 6094 3University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 6089 1University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 6089 2University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 6089 3
...ta to be Presented April 15th at EASL Conference i...pril 11, 2007,/PRNewswire-FirstCall/ - MIGENIX Inc...ious diseases, has received new top-line results,c...s (November 6,2006) indicating evidence of clinic...study using the oral alpha-glucosidase,inhibitor, ...
...MBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gl...d biopharmaceutical,company, announced today that ...omidepsin will be presented at the 2007,Annual Mee...h,taking place in Los Angeles, CA April 14-18, 200...preclinical research,performed by multiple academi...
Other Medicine Technology:New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: